PDO Screen

Patient-derived colorectal cancer organoid screening platform


Test your compound efficacy directly on patient avatars to uncover the therapeutic potential of your agent early in the drug development pipeline. 


Screen features:

  • ATP-based cell-viability assay with IC50 readouts
  • 3D assay format with 96/384-well plate format
  • Test up to 10 compounds in triplicates
  • A preset panel of CRC organoid models capturing key cancer drivers
  • Matched tumor-normal organoid pairs available to uncover off-tumor toxicities

enroll now

Book your screen now!